Company intelligence / Profile preview
Sinocelltech Group Limited
Beijing（北京）, Beijing Municipality（北京市）, 中国（China）sinocelltech.com ↗
- Ownership
- Private
- Employees
- ~2313
- Development stage
- Commercial
01
Overview
Sinocelltech has several approved drugs in China including monoclonal antibodies for cancer and autoimmune diseases as well as recombinant vaccines against COVID variants. The company also has late-stage clinical assets targeting HPV and SARS-CoV‑2. Its technologies focus on reducing the cost of biologics manufacturing to increase accessibility
- Therapeutic areas
- GastroenterologyImmunologyHematologyOncologyInfectious Diseases
- Modalities
- Monoclonal antibodiesrecombinant proteinsprophylactic vaccinesbiosimilars
- Industry
- Biotech
02
Drug pipeline
37 assets36 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Sinocelltech Group Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sinocelltech Group Limited.